CPSF7

Across TCGA pan-cancer cohorts, CPSF7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CPSF7 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CPSF7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPSF7 expression acts as an unfavorable survival marker.

KIRC, OV, and ESCA are the cancer types where CPSF7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.062	0.865	<.001	24	view →
OV	DFS	Median	All	0.132	0.541	.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CPSF7–KIRC (DFS)

Open the KIRC breakdown →